Evidence map›Paper›PMID 36292618›Full record

ArticleGenes2022

Nevio Sarmento, Ella M Meumann, Helder M Pereira, Constantino Lopes, Maria Globan, Charlotte Hall, Matthew Di Palma, Nicole Hersch, Kristy Horan, Anna P Ralph and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The COVID-19 laboratory response in Timor-Leste; a story of collaboration.The Lancet regional health. Southeast Asia · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nevio SarmentoMenzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
Ella M MeumannMenzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
Helder M PereiraNational TB Reference Laboratory, National Health Laboratory, Dili, Timor-Leste.
Constantino LopesNational Tuberculosis Control Program, Ministry of Health, Dili, Timor-Leste.
Maria GlobanVictorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Charlotte HallMaluk Timor, Dili, Timor-Leste.
Matthew Di PalmaBairo Pite Clinic, Dili, Timor-Leste.
Nicole HerschBairo Pite Clinic, Dili, Timor-Leste.
Kristy HoranThe Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
Anna P RalphMenzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.ORCID 0000-0002-2253-5749
Joshua R FrancisMenzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.ORCID 0000-0001-9302-4543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is prevalent and a major public health problem in Timor-Leste. The government of Timor-Leste is prioritising the surveillance of TB and drug-susceptibility testing (DST) to understand the burden of TB and TB drug resistance in the country. Moreover, little is known about the origin of

Indexed as

Mycobacterium tuberculosisEthambutolGenotypeHumansIsoniazidPilot ProjectsPyrazinamideRifampinTimor-LesteEthambutolIsoniazidPyrazinamideRifampincultureeast TimorsensitivitysequencingTuberculosis (TB)

Identifiers

PMID36292618
PMCPMC9602296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.